IEED

(redirected from Involuntary Emotional Expression Disorder)
AcronymDefinition
IEEDOffice of Indian Energy and Economic Development (US DOI)
IEEDInvoluntary Emotional Expression Disorder
IEEDIndo-European Etymological Dictionary (Leiden University; Netherlands; research project)
IEEDInstitute for Entrepreneurship and Enterprise Development (Lancaster University Management School; UK)
References in periodicals archive ?
Involuntary emotional expression disorder (IEED) has been found to occur in 16.
Involuntary emotional expression disorder (IEED) is also known as pseudobulbar affect and pathologic laughing or crying.
Zenvia, AVANIR's lead product candidate for the treatment of involuntary emotional expression disorder (IEED), is the subject of an approvable letter from the FDA and future development plans for this product candidate are under consideration.
AVANIR's lead product candidate Zenvia is being developed for the treatment of pseudobulbar affect (PBA), also known as involuntary emotional expression disorder, and is the subject of an approvable letter from the FDA for that indication.
Involuntary emotional expression disorder (IEED) is a condition that manifests as episodes of crying, laughing, or both and is a result of structural brain damage (Cummings et al.
16) Involuntary emotional expression disorder (IEED)--or pathologic laughing or crying--is a form of pseudobulbar affect.
Damage to the descending inputs to the pontomedullary area once referred to as the faciorespiratory center is most likely to result in release of bulbar function and, subsequently, involuntary emotional expression disorder (IEED).
We will use $11 million of the sales proceeds to pay down a portion of our outstanding notes and believe our remaining net available funds will be sufficient to finance operating expenses for at least the next year, including funding the initiation of both our planned confirmatory Phase III clinical trials of Zenvia in patients with involuntary emotional expression disorder (IEED) and with diabetic peripheral neuropathic (DPN) pain.
Avanir Pharmaceuticals (NASDAQ:AVNR) today announced that data on the long-term safety of the investigational drug Zenvia[TM] (dextromethorphan / quinidine) and the prevalence of Involuntary Emotional Expression Disorder (IEED) were presented today during a poster session at the American Academy of Neurology (AAN) 59th Annual Meeting in Boston.
Avanir now has two Phase III Zenvia programs in areas with significant unmet medical need, one in Involuntary Emotional Expression Disorder (IEED) and one in diabetic neuropathic pain.
Zenvia[TM], AVANIR's lead product candidate for the treatment of involuntary emotional expression disorder (IEED), is the subject of an approvable letter from the FDA.
Food and Drug Administration (FDA) officials to address concerns expressed in the FDA's October 30, 2006 approvable letter for Zenvia[TM] as a treatment for involuntary emotional expression disorder (IEED) and to present AVANIR's proposed strategy to gain approval for Zenvia for this indication.